Isomorphic Labs Secures $2.1 Billion to Revolutionize AI-Driven Drug Design
TL;DR
- Isomorphic Labs, a DeepMind spinout, raised $2.1 billion in Series B funding led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
- The capital will supercharge the company's AI drug design engine, IsoDDE, to scale operations globally and fast-track drug candidates into clinical trials.
- This massive investment validates AI's transformative potential in drug discovery, building on tech like AlphaFold to deliver breakthroughs in multiple therapeutic areas.
Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
— Isomorphic Labs (@IsomorphicLabs) May 12, 2026
This milestone… pic.twitter.com/NMP4r40wtt
A Game-Changing Funding Milestone
Isomorphic Labs, the AI powerhouse spun out from Google DeepMind, just clinched a staggering $2.1 billion in Series B funding—a clear signal that big money is betting big on AI to crack the code of drug discovery. Announced today, the round was led by Thrive Capital, their second consecutive lead investment, and drew heavy hitters including existing backers Alphabet and GV, plus newcomers like Abu Dhabi's MGX, Singapore's Temasek, CapitalG, and the UK's Sovereign AI Fund. Coming on the heels of a $600 million raise last year, this infusion catapults the London-based firm into hyperdrive, positioning it to redefine how we design life-saving medicines.
Powering the IsoDDE Engine
At the heart of Isomorphic's ambition lies IsoDDE, its proprietary AI drug design engine that's already proving its mettle. This funding will turbocharge its development and deployment, enabling the company to tackle complex biological challenges with unprecedented precision and speed. Drawing from DeepMind's AlphaFold legacy—including the advanced AlphaFold 3, which predicts molecular structures and interactions—IsoDDE integrates cutting-edge AI models to reimagine drug discovery as an engineering discipline. No longer bogged down by trial-and-error, researchers can now simulate and optimize drug candidates at scale, slashing timelines from years to months.
Accelerating the Drug Pipeline
The real excitement? This cash will propel Isomorphic's in-house pipeline across multiple therapeutic areas and drug modalities toward the clinic. With first clinical trials eyed for late 2026, the company is shifting from proof-of-concept to real-world impact, aiming to deliver treatments for millions facing unmet medical needs. Partnerships with pharma giants like Eli Lilly and Novartis already underscore the tech's viability, and this funding extends that runway, giving Isomorphic the resources to expand programs without the immediate pressure of an IPO or further fundraising.
Global Scale and Talent Surge
Isomorphic isn't stopping at tech upgrades. The investment will fuel aggressive global expansion, including hiring top-tier AI engineers, drug designers, and clinical experts across its sites. CEO Demis Hassabis, who also leads DeepMind, called it a "massive vote of confidence" in their AI-first approach, emphasizing the need to scale tech to its full potential. Alphabet's Ruth Porat echoed the sentiment, praising the firm's "extraordinary progress" in harnessing AI for faster drug discovery. This talent influx is crucial for addressing the world's disease burden through integrated science and proprietary data.
Implications for AI in Biotech
This isn't just another funding round—it's a pivotal moment for biotech. Isomorphic's first-principles strategy, blending AI innovation with deep biological insight, challenges the status quo of a $100 billion-plus industry plagued by high failure rates and ballooning costs. By making AI-designed drugs a reality, the company could usher in an era of precision medicine, where therapies are tailored faster and more effectively. As Hassabis puts it, they've shown their approach is "fundamentally sound"—now it's about unleashing it globally. Investors and patients alike are watching closely as Isomorphic Labs races toward breakthroughs once thought impossible.
Get All The Latest Updates Delivered Straight To Your Inbox For Free!